Business
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc.  ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Closes $1.3 M Non-Brokered Private PlacementToronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering (\"Offering\") of units (\"Units\"). On closing, the Corporation issued an aggregate of 7,850,882 Units at a price of $CAN 0.17 per Unit for aggregate gross proceeds of approximately $CAN 1,334,650.Each Unit consists of one common share of the Company (\"Common Share\") and one common share purchase warrant (\"Warrant\"). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.21 per share for a period of 5 years following the date of closing.The Company plans to use the proceeds of the financing to further the Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study currently underway, working capital and general corporate purposes.In connection with the Offering, the Company paid a finder's fee of $31,658, of which $15,470 was paid in cash and $16,188 was paid through the issuance of 95,221 common shares. In addition, the Company issued 186,221 non-transferable finder warrants. Each finder warrant is exercisable into one common share at an exercise price of $0.21 per share for a period of 5 years following the date of closing.The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (\"U.S. Securities Act\"), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for, the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States. unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirement is available. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities offered...